Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.27M$2.27Mderivedno prior Q4 2023 on file Net Income-$21.20M-$21.20MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$23,040,000N/M Operating Cash Flowderived-$7,495,000N/M Free Cash Flowderived-$8,947,000N/M Margins · derivedOperating margin-1014.5%
Net margin-933.5%
ended Dec 31, 2024 · filed Mar 18, 2025 · 77 d after period end